OA12609A - An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. - Google Patents

An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. Download PDF

Info

Publication number
OA12609A
OA12609A OA1200300303A OA1200300303A OA12609A OA 12609 A OA12609 A OA 12609A OA 1200300303 A OA1200300303 A OA 1200300303A OA 1200300303 A OA1200300303 A OA 1200300303A OA 12609 A OA12609 A OA 12609A
Authority
OA
OAPI
Prior art keywords
amino
alkyl
adenosine
sait
diphenylethyl
Prior art date
Application number
OA1200300303A
Other languages
English (en)
Inventor
Roisin A Armstrong
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12609A publication Critical patent/OA12609A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200300303A 2001-05-25 2002-05-24 An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. OA12609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
OA12609A true OA12609A (en) 2006-06-09

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300303A OA12609A (en) 2001-05-25 2002-05-24 An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.

Country Status (22)

Country Link
US (1) US20040171576A1 (xx)
EP (1) EP1395287A1 (xx)
KR (1) KR20030097901A (xx)
CN (1) CN1535161A (xx)
AP (1) AP2003002911A0 (xx)
BG (1) BG108383A (xx)
BR (1) BR0209986A (xx)
CA (1) CA2448086A1 (xx)
CO (1) CO5540324A2 (xx)
CZ (1) CZ20033126A3 (xx)
EE (1) EE200300586A (xx)
HU (1) HUP0400029A2 (xx)
IL (1) IL158774A0 (xx)
MA (1) MA27028A1 (xx)
MX (1) MXPA03010787A (xx)
NO (1) NO20035202D0 (xx)
OA (1) OA12609A (xx)
PA (1) PA8546101A1 (xx)
PL (1) PL366899A1 (xx)
SK (1) SK14302003A3 (xx)
SV (1) SV2003001055A (xx)
WO (1) WO2002096462A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PE20080036A1 (es) 2005-10-21 2008-03-06 Novartis Ag Anticuerpos humanos para la interleucina-13 (il13)
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2347512C (en) * 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
CO5540324A2 (es) 2005-07-29
MXPA03010787A (es) 2004-03-02
NO20035202D0 (no) 2003-11-24
SV2003001055A (es) 2003-11-14
WO2002096462A1 (en) 2002-12-05
BR0209986A (pt) 2004-04-06
AP2003002911A0 (en) 2003-12-31
EE200300586A (et) 2004-04-15
MA27028A1 (fr) 2004-12-20
PA8546101A1 (es) 2003-12-10
IL158774A0 (en) 2004-05-12
BG108383A (bg) 2004-08-31
CZ20033126A3 (cs) 2004-09-15
SK14302003A3 (sk) 2004-08-03
CN1535161A (zh) 2004-10-06
HUP0400029A2 (hu) 2004-04-28
CA2448086A1 (en) 2002-12-05
PL366899A1 (en) 2005-02-07
KR20030097901A (ko) 2003-12-31
US20040171576A1 (en) 2004-09-02
EP1395287A1 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
OA12609A (en) An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
US7107985B2 (en) Pharmaceutical combination
OA12610A (en) A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
AU2002351066B2 (en) Pharmaceutical combinations of adenosine A-2a and beta-2-adrenergic receptor agonists
US20030109485A1 (en) Pharmaceutical combination
NZ533030A (en) Combination of a selective PDE4 inhibitor and an adrenergic beta-2 receptor agonist
AU2002316924A1 (en) An adenosine A2A receptor agonist and an anticholiergic agent in combination for treating obstructive airways diseases
AU2002344167A1 (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ZA200308602B (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.